NCT01482871 - Safety Study of ALG- 1001 to Treat Diabetic Macular Edema | Biotech Hunter

Timeline

Start Date

January 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Diabetic Macular Edema

Interventions

DRUG

ALG-1001

1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops

DRUG

ALG-1001

2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops

DRUG

ALG-1001

5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops

DRUG

ALG-1001

7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops

Trial Locations (1)

Apec Hospital La Ceguera, Mexico City